Skip to main content

Table 1 RTOG 1308 dosimetric compliance criteria for target volumes and normal structures

From: Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC

RT Parameter

Per protocol

Variation acceptable

% of PTV covered by prescription dose

95 %

≥95 % of the PTV is covered by ≥95 % of the prescription dose

% of ITV (motion-incorporated CTV)

100 %

≥99 %

Maximum PTV dose PTV (0.03 cc)

≤120 % RX

≤125 % RX

Minimum PTV dose (0.03 cc)

≥85 % RX

≥75 % RX

Normal lung (Both lungs minus GTV)

V5 ≤ 60 %

V5 ≤ 65 %

V20 ≤ 37 %

V20 ≤ 40 %

Mean dose < 20 Gy (RBE)

Mean Dose: ≤ 22 Gy (RBE)

Esophagus

Max dose: 74 Gy (RBE) ≤ 1 cc of partial circumference

Max dose: 74 Gy (RBE) ≤ 1.5 cc of partial circumference

Brachial Plexus

V66 ≤ 2.0 cc

V66 ≤ 2.5 cc

V70 ≤ 1.0 cc

V70 ≤ 1.5 cc

V74 ≤ 0.5 cc

V74 ≤ 1.0 cc

V75 ≤ 0.1 cc

V75 ≤ 0.5 cc

Spinal Cord

V50 < 0.03 cc

V52 < 0.03 cc

Heart

V30 ≤ 50 %

50 % ≤ V30 ≤ 55 %

V45 ≤ 35 %

35 % ≤ V45 ≤ 40 %

  1. RX prescription dose